Institutional Investor Files Intent to Sell $9.45M in Shares Following FDA Rejection
UNCY sits 47% above its 52-week low of $3.71 on elevated volume (4.6× avg).
Summary
An institutional investor with a board seat intends to sell $9.45 million worth of Unicycive Therapeutics shares, immediately following the FDA's rejection of the company's lead drug.
Key Events · Ownership and Investor Activity · UNCY
-
Intent to Sell Significant Stake
Vivo Opportunity Fund Holdings, L.P. filed a Form 144 to sell 1,789,916 shares, valued at approximately $9.45 million.
-
Timing Coincides with FDA Rejection
The intent to sell was filed on June 30, 2026, the same day the company announced the FDA declined to approve its drug for elevated phosphate levels.
-
Material Sale for Company Size
The proposed sale represents about 6.7% of the company's current market capitalization, indicating a significant reduction in exposure by a major shareholder.
Analysis · UNCY · Life Sciences
Vivo Opportunity Fund Holdings, L.P., an institutional investor with a director relationship, has filed a Form 144 indicating intent to sell a substantial block of shares. This filing comes on the same day the company announced the FDA's decline to approve its key drug, suggesting a rapid reaction to the significant regulatory setback. The proposed sale represents a material portion of the company's market capitalization.
At the time of this filing, UNCY was trading at $5.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $141M. The 52-week trading range was $3.71 to $8.74. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.